STAT April 22, 2024
Jennifer Handt

In human biology, the protein dystrophin is a shining example of Joni Mitchell’s classic line, “you don’t know what you’ve got ’til it’s gone.” Dystrophin stabilizes muscle cells. In its absence, the house of cards comes down.

For my 6-year-old son, Charlie, dystrophin will govern how long he lives. And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation.

Charlie has Duchenne muscular dystrophy, a degenerative genetic disease that, until recently, has guaranteed death by early adulthood from cardiac or respiratory failure. Like all people with Duchenne, Charlie’s muscles are not coded to produce dystrophin protein, with catastrophic effects from his first days of life.

Drug discovery efforts...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Project Optimus: helping or hindering cancer drug development?
Cancer screenings, menthols and the moonshot
The Time Is Now For Federal Reform Of Direct-To-Consumer Advertising Of Prescription Drugs
Regulatory tracker: FDA offers Pfizer's Tivdak full nod in cervical cancer
Next-generation psychedelic workers

Share This Article